These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 26471242)

  • 1. Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with acute myeloid leukemia.
    Kobayashi Y; Yamauchi T; Kiyoi H; Sakura T; Hata T; Ando K; Watabe A; Harada A; Taube T; Miyazaki Y; Naoe T
    Cancer Sci; 2015 Nov; 106(11):1590-5. PubMed ID: 26471242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with advanced solid tumors.
    Nokihara H; Yamada Y; Fujiwara Y; Yamamoto N; Wakui H; Nakamichi S; Kitazono S; Inoue K; Harada A; Taube T; Takeuchi Y; Tamura T
    Invest New Drugs; 2016 Feb; 34(1):66-74. PubMed ID: 26627079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies.
    Lin CC; Su WC; Yen CJ; Hsu CH; Su WP; Yeh KH; Lu YS; Cheng AL; Huang DC; Fritsch H; Voss F; Taube T; Yang JC
    Br J Cancer; 2014 May; 110(10):2434-40. PubMed ID: 24755882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of volasertib, a Polo-like kinase inhibitor, plus platinum agents in solid tumors: safety, pharmacokinetics and activity.
    Awada A; Dumez H; Aftimos PG; Costermans J; Bartholomeus S; Forceville K; Berghmans T; Meeus MA; Cescutti J; Munzert G; Pilz K; Liu D; Schöffski P
    Invest New Drugs; 2015 Jun; 33(3):611-20. PubMed ID: 25794535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 1 dose escalation trial of volasertib in combination with decitabine in patients with acute myeloid leukemia.
    Cortes J; Podoltsev N; Kantarjian H; Borthakur G; Zeidan AM; Stahl M; Taube T; Fagan N; Rajeswari S; Uy GL
    Int J Hematol; 2021 Jan; 113(1):92-99. PubMed ID: 32951163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Randomized, Open-Label Phase II Trial of Volasertib as Monotherapy and in Combination With Standard-Dose Pemetrexed Compared With Pemetrexed Monotherapy in Second-Line Treatment for Non-Small-Cell Lung Cancer.
    Ellis PM; Leighl NB; Hirsh V; Reaume MN; Blais N; Wierzbicki R; Sadrolhefazi B; Gu Y; Liu D; Pilz K; Chu Q
    Clin Lung Cancer; 2015 Nov; 16(6):457-65. PubMed ID: 26100229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours.
    Schöffski P; Awada A; Dumez H; Gil T; Bartholomeus S; Wolter P; Taton M; Fritsch H; Glomb P; Munzert G
    Eur J Cancer; 2012 Jan; 48(2):179-86. PubMed ID: 22119200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An open-label, single-arm, phase 2 trial of the Polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer.
    Stadler WM; Vaughn DJ; Sonpavde G; Vogelzang NJ; Tagawa ST; Petrylak DP; Rosen P; Lin CC; Mahoney J; Modi S; Lee P; Ernstoff MS; Su WC; Spira A; Pilz K; Vinisko R; Schloss C; Fritsch H; Zhao C; Carducci MA
    Cancer; 2014 Apr; 120(7):976-82. PubMed ID: 24339028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy.
    Döhner H; Lübbert M; Fiedler W; Fouillard L; Haaland A; Brandwein JM; Lepretre S; Reman O; Turlure P; Ottmann OG; Müller-Tidow C; Krämer A; Raffoux E; Döhner K; Schlenk RF; Voss F; Taube T; Fritsch H; Maertens J
    Blood; 2014 Aug; 124(9):1426-33. PubMed ID: 25006120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I dose-escalation study of volasertib in pediatric patients with acute leukemia or advanced solid tumors.
    Doz F; Locatelli F; Baruchel A; Blin N; De Moerloose B; Frappaz D; Dworzak M; Fischer M; Stary J; Fuertig R; Riemann K; Taube T; Reinhardt D
    Pediatr Blood Cancer; 2019 Oct; 66(10):e27900. PubMed ID: 31276318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, open-label, phase I/II trial to investigate the maximum tolerated dose of the Polo-like kinase inhibitor BI 2536 in elderly patients with refractory/relapsed acute myeloid leukaemia.
    Müller-Tidow C; Bug G; Lübbert M; Krämer A; Krauter J; Valent P; Nachbaur D; Berdel WE; Ottmann OG; Fritsch H; Munzert G; Garin-Chesa P; Fleischer F; Taube T; Döhner H
    Br J Haematol; 2013 Oct; 163(2):214-22. PubMed ID: 24033250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An open-label, phase I study of the polo-like kinase-1 inhibitor, BI 2536, in patients with advanced solid tumors.
    Hofheinz RD; Al-Batran SE; Hochhaus A; Jäger E; Reichardt VL; Fritsch H; Trommeshauser D; Munzert G
    Clin Cancer Res; 2010 Sep; 16(18):4666-74. PubMed ID: 20682708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I study of volasertib combined with afatinib, in advanced solid tumors.
    Machiels JP; Peeters M; Herremans C; Surmont V; Specenier P; De Smet M; Pilz K; Strelkowa N; Liu D; Rottey S
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):843-51. PubMed ID: 26349473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.
    Perl AE; Altman JK; Cortes J; Smith C; Litzow M; Baer MR; Claxton D; Erba HP; Gill S; Goldberg S; Jurcic JG; Larson RA; Liu C; Ritchie E; Schiller G; Spira AI; Strickland SA; Tibes R; Ustun C; Wang ES; Stuart R; Röllig C; Neubauer A; Martinelli G; Bahceci E; Levis M
    Lancet Oncol; 2017 Aug; 18(8):1061-1075. PubMed ID: 28645776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of PLK1 by capped-dose volasertib exerts substantial efficacy in MDS and sAML while sparing healthy haematopoiesis.
    Dill V; Kauschinger J; Hauch RT; Buschhorn L; Odinius TO; Müller-Thomas C; Mishra R; Kyncl MC; Schmidt B; Prodinger PM; Hempel D; Bellos F; Höllein A; Kern W; Haferlach T; Slotta-Huspenina J; Bassermann F; Peschel C; Götze KS; Waizenegger IC; Höckendorf U; Jost PJ; Jilg S
    Eur J Haematol; 2020 Feb; 104(2):125-137. PubMed ID: 31758597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
    DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
    Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical profile of gilteritinib in Japanese patients with relapsed/refractory acute myeloid leukemia: An open-label phase 1 study.
    Usuki K; Sakura T; Kobayashi Y; Miyamoto T; Iida H; Morita S; Bahceci E; Kaneko M; Kusano M; Yamada S; Takeshita S; Miyawaki S; Naoe T
    Cancer Sci; 2018 Oct; 109(10):3235-3244. PubMed ID: 30039554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential Drug-Drug Interactions with Combination Volasertib + Itraconazole: A Phase I, Fixed-sequence Study in Patients with Solid Tumors.
    Lang I; Liu D; Fritsch H; Taube T; Chizhikov E; Liptai B
    Clin Ther; 2020 Nov; 42(11):2214-2224. PubMed ID: 33139055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I, dose-escalation study of volasertib combined with nintedanib in advanced solid tumors.
    de Braud F; Cascinu S; Spitaleri G; Pilz K; Clementi L; Liu D; Sikken P; De Pas T
    Ann Oncol; 2015 Nov; 26(11):2341-6. PubMed ID: 26395347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population Pharmacokinetics of Volasertib Administered in Patients with Acute Myeloid Leukaemia as a Single Agent or in Combination with Cytarabine.
    P Solans B; Fleury A; Freiwald M; Fritsch H; Haug K; Trocóniz IF
    Clin Pharmacokinet; 2018 Mar; 57(3):379-392. PubMed ID: 28631179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.